Physician profile
Melissa Su
NPI 1801834858
$796.30
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $664 · 2020: $110 · 2022: $22.26.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $314.57 | 2019-2020 | |
| Amarin Pharma, INC. | $88.40 | 2019-2020 | |
| Lilly USA, LLC | $78.20 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $66.00 | 2019 | |
| Radius Health, INC. | $49.53 | 2019 | |
| Glaxosmithkline, LLC. | $39.82 | 2019 | |
| Amgen INC. | $25.75 | 2019-2020 | |
| Abbott Laboratories | $22.26 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.08 | 2020 | |
| Allergan, INC. | $14.04 | 2020 | |
| Astellas Pharma US INC | $12.41 | 2020 | |
| Aytu Biopharma, INC. | $12.28 | 2019 | |
| Sanofi Pasteur INC. | $12.16 | 2019 | |
| Abbvie INC. | $11.66 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.21 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $11.09 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10.84 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Su listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.